As of 2024-12-13, the EV/EBITDA ratio of Elicera Therapeutics AB (ELIC.ST) is -1.36. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ELIC.ST's latest enterprise value is 29.43 mil SEK. ELIC.ST's TTM EBITDA according to its financial statements is -21.62 mil SEK. Dividing these 2 quantities gives us the above ELIC.ST EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.2x - 7.8x | 6.5x |
| Forward P/E multiples | 6.1x - 9.1x | 7.6x |
| Fair Price | (2.81) - (3.87) | (3.41) |
| Upside | -258.2% - -317.9% | -291.9% |
| Date | EV/EBITDA |
| 2024-12-10 | -1.13 |
| 2024-12-09 | -1.18 |
| 2024-12-06 | -1.11 |
| 2024-12-05 | -1.11 |
| 2024-12-04 | -1.23 |
| 2024-12-03 | -1.37 |
| 2024-12-02 | -1.42 |
| 2024-11-29 | -1.46 |
| 2024-11-28 | -1.17 |
| 2024-11-27 | -1.23 |
| 2024-11-26 | -1.25 |
| 2024-11-25 | -1.26 |
| 2024-11-22 | -1.30 |
| 2024-11-21 | -1.34 |
| 2024-11-20 | -1.38 |
| 2024-11-19 | -1.47 |
| 2024-11-18 | -1.52 |
| 2024-11-15 | -1.50 |
| 2024-11-14 | -1.49 |
| 2024-11-13 | -1.67 |
| 2024-11-12 | -1.68 |
| 2024-11-11 | -1.59 |
| 2024-11-08 | -1.39 |
| 2024-11-07 | -1.50 |
| 2024-11-06 | -1.57 |
| 2024-11-05 | -1.69 |
| 2024-11-04 | -1.41 |
| 2024-11-01 | -1.52 |
| 2024-10-31 | -1.55 |
| 2024-10-30 | -1.69 |
| 2024-10-29 | -1.81 |
| 2024-10-28 | -1.76 |
| 2024-10-25 | -1.40 |
| 2024-10-24 | -1.25 |
| 2024-10-23 | -1.00 |
| 2024-10-22 | -0.97 |
| 2024-10-21 | -0.93 |
| 2024-10-18 | -0.96 |
| 2024-10-17 | -1.14 |
| 2024-10-16 | -1.04 |
| 2024-10-15 | -1.06 |
| 2024-10-14 | -0.75 |
| 2024-10-11 | -0.75 |
| 2024-10-10 | -0.75 |
| 2024-10-09 | -0.66 |
| 2024-10-08 | -0.72 |
| 2024-10-07 | -0.93 |
| 2024-10-04 | -1.08 |
| 2024-10-03 | -0.97 |
| 2024-10-02 | -1.04 |